News stories about Baxter International (NYSE:BAX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Baxter International earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.7950944187749 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Baxter International Inc. (BAX) – Investors Alert on Unusual Volume Move – Wall Street Morning (wallstreetmorning.com)
- Hot Stock’s Watch List – Baxter International Inc (NYSE: BAX) – Stocks Pen (stockspen.com)
- Durable Medical Equipment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025 (markets.businessinsider.com)
- Global Antiemetic Market Opportunities 2018: Astellas Pharma, Novartis AG, , Baxter International (marketwatch.com)
- Baxter International Inc. (BAX) Stock Try To Grab Potentials on Technical Facts – Investing News Update (investingbizz.com)
A number of equities analysts have commented on the stock. Barclays upped their price objective on shares of Baxter International from $73.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. BMO Capital Markets upped their price objective on shares of Baxter International from $74.00 to $77.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Royal Bank of Canada restated a “hold” rating and set a $72.00 price objective on shares of Baxter International in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Baxter International from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Finally, Raymond James Financial upgraded shares of Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price objective for the company in a research report on Wednesday, January 3rd. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $71.00.
Baxter International (NYSE:BAX) opened at $68.09 on Wednesday. The stock has a market cap of $36,999.51, a PE ratio of 52.78, a PEG ratio of 1.97 and a beta of 0.82. Baxter International has a twelve month low of $51.03 and a twelve month high of $72.58. The company has a quick ratio of 2.05, a current ratio of 2.57 and a debt-to-equity ratio of 0.38.
Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.77 billion. Baxter International had a net margin of 6.79% and a return on equity of 15.11%. The firm’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.57 EPS. analysts forecast that Baxter International will post 2.78 earnings per share for the current fiscal year.
Baxter International announced that its Board of Directors has approved a share buyback plan on Tuesday, February 20th that allows the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 2nd. Investors of record on Friday, March 2nd will be paid a $0.16 dividend. The ex-dividend date is Thursday, March 1st. This represents a $0.64 dividend on an annualized basis and a yield of 0.94%. Baxter International’s payout ratio is 49.61%.
In related news, Director Carole J. Shapazian sold 4,990 shares of the stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $66.05, for a total value of $329,589.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Giuseppe Accogli sold 28,641 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total transaction of $1,918,947.00. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was posted by Equities Focus and is the sole property of of Equities Focus. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.equitiesfocus.com/2018/03/14/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-baxter-international-bax-share-price.html.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.